Patent ID: 7781404
Filing Date: 2010-08-24
Classification: A61K,C07K

Abstract:
1. A pharmaceutical composition comprising a chimeric IGF polypeptide and a pharmaceutically acceptable carrier, wherein the chimeric IGF polypeptide comprises in an N-terminus to a C-terminus direction: (a) an IGF2-derived component comprising amino acid 7 through amino acid 37 of IGF2 (SEQ ID NO:3) and an IGF-1-derived component comprising amino acid 38 to amino acid 64 of IGF1 (SEQ ID NO:1), or (b) an IGF1-derived component comprising amino acid 4 to amino acid 36 of SEQ ID NO:1 and an IGF2-derived component comprising amino acid 39 to amino acid 64 of IGF2, and optionally (c) a fusion component (F) at the C-terminus, and/or (d) a signal sequence at the N-terminus, wherein F is selected from the group consisting of a human IgG constant region, Fc domain, and heavy chain.